GI-6301: Phase II started

GlobeImmune began the double-blind, U.S. Phase II GI-6301-02 trial to evaluate subcutaneous GI-6301 plus radiotherapy in about 50 patients. Patients will receive

Read the full 220 word article

How to gain access

Continue reading with a
two-week free trial.